Lomefloxacin Hydrochloride

CHEMBL1728 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
387.8 g/mol
LogP
Phase
4

The hydrochloride salt form of lomefloxacin, a fluoroquinolone antibiotic used for urinary and respiratory bacterial infections. It shares the DNA-inhibiting mechanism of the parent compound.

Berat Molekul

387,8000 g/mol

TPSA

72,90 Ų

Mekanisme Kerja

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21.Cl

InChI

InChI=1S/C17H19F2N3O3.ClH/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22;/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25);1H

Molecular Formula

C17H20ClF2N3O3

HBD / HBA

3 / 8

Ikatan yang Dapat Dirotasi

3

Atom Berat

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The hydrochloride salt form of lomefloxacin, a fluoroquinolone antibiotic used for urinary and respiratory bacterial infections. It shares the DNA-inhibiting mechanism of the parent compound.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Lomefloxacin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1728. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 68624. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.